Trade To Black Podcast: States Prepared For FDA Psychedelic Approval

Federal guidelines issued by SAMHSA advise states to prepare infrastructure for upcoming FDA approvals of psychedelic-assisted therapies. This regulatory momentum highlights the need for oversight, credentialing, and coverage protocols before treatments enter clinical settings. Guest Matthew "Whiz" Buckley shares insights on the rapid policy shift regarding substances like ibogaine and psilocybin. The discussion addresses international treatment tourism risks, the necessity of rigorous medical screening, and how major pharmaceutical companies might approach emerging psychedelic models. In additional segments, the panel analyzes consumer demand for higher safety standards in cannabis markets and reviews operational challenges within federal CBD pilot programs.